CLINICAL OUTCOMES

References

^{* Study reported with a majority as TASC A&B lesion and/or majority as Rutherford Class 2 and 3.
** Nominal deployment is defined as the stent length upon deployment being within +/- 10% of the labeled stent length. This data is from a non-powered post-hoc analysis.
*** 2011年時データ}

1. Brescia AA. et al., J Vasc Surg. 2015 Jun;61(6):1472-8. 2. Chan YC. et al., J Vasc Surg. 2015 Nov;62(5):1201-9. 3. Dumantepe M. Vasc Endovascular Surg. 2017 Jul;51(5):240-246. 4. Garcia L. et al., Catheterization and Cardiovascular Interventions 2017 Jun 1;89(7):1259-1267. 5. George JC. et al., J Vasc Interv Radiol. 2014 Jun;25(6):954-61. 6. Goltz JP. et al., J Endovasc Ther. 2012 Jun;19(3):450-6. 7. León LR Jr. et al., J Vasc Surg. 2013 Apr;57(4):1014-22. 8. Montero-Baker M. et al., J Vasc Surg. 2016 Oct;64(4):1002-8. 9. Myint M. et al., J Endovasc Ther. 2016 Jun;23(3):433-41. 10. Palena LM. et al., J Endovasc Ther. 2018 Oct;25(5):588-591. 11. Scheinert D. et al., JACC Cardiovasc Interv. 2013 Jan;6(1):65-71. 12. Scheinert D. et al., J Endovasc Ther. 2011 Dec;18(6):745-52. 13. Steiner S. et al., J Endovasc Ther. 2016 Apr;23(2):347-55. 14. Werner M. et al., EuroIntervention. 2014 Nov;10(7):861-8. 15. San Norberto EM. et al., Ann Vasc Surg. 2017 May;41:186-195. 16. Teymen B. et al., Vascular. 2018 Feb;26(1):54-61. 17. Bhatt H. et al., Cardiovasc Revasc Med. 2018 Jul;19(5 Pt A):512-515.